LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 72 | hr | 1401 | 692 | 4223 | 0.1640 | -0.2512 |
| MDA-MB-231 | A443654 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 414 | 4513 | 0.0917 | -0.2508 |
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 694 | 4223 | 0.1643 | -0.2508 |
| MDA-MB-231 | Alvocidib | 10.0 | uM | LJP6 | 72 | hr | 1235 | 414 | 4513 | 0.0918 | -0.2507 |
| BT-20 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 427 | 3769 | 0.1135 | -0.2506 |
| BT-20 | Omipalisib | 10.0 | uM | LJP6 | 72 | hr | 1097 | 428 | 3769 | 0.1135 | -0.2504 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 696 | 4223 | 0.1650 | -0.2498 |
| MCF7 | A443654 | 0.37 | uM | LJP6 | 72 | hr | 1209 | 491 | 4093 | 0.1200 | -0.2492 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 420 | 4513 | 0.0932 | -0.2487 |
| BT-20 | A443654 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 437 | 3769 | 0.1161 | -0.2468 |
| MDA-MB-231 | Torin2 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 428 | 4513 | 0.0948 | -0.2465 |
| MCF7 | Mitoxantrone | 3.33 | uM | LJP6 | 72 | hr | 1209 | 499 | 4093 | 0.1219 | -0.2464 |
| MDA-MB-231 | Alvocidib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 432 | 4513 | 0.0957 | -0.2453 |
| MCF7 | LDN-193189 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 502 | 4093 | 0.1227 | -0.2453 |
| MCF7 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 502 | 4093 | 0.1228 | -0.2452 |
| MDA-MB-231 | PF431396 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 433 | 4513 | 0.0959 | -0.2450 |
| MCF7 | BMS345541 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 503 | 4093 | 0.1230 | -0.2449 |
| SK-BR-3 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 711 | 4223 | 0.1684 | -0.2447 |
| MDA-MB-231 | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 1235 | 436 | 4513 | 0.0967 | -0.2439 |
| MCF7 | NVP-TAE684 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 508 | 4093 | 0.1243 | -0.2431 |
| MDA-MB-231 | WZ3105 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 446 | 4513 | 0.0989 | -0.2409 |
| BT-20 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 454 | 3769 | 0.1206 | -0.2405 |
| MDA-MB-231 | Alvocidib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 447 | 4513 | 0.0992 | -0.2405 |
| MDA-MB-231 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 448 | 4513 | 0.0994 | -0.2402 |
| BT-20 | AZD7762 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 456 | 3769 | 0.1211 | -0.2398 |